Chemistry:Sifalimumab
From HandWiki
Short description: Human monoclonal antibody
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Interferon α |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6518H10008N1724O2032S38 |
| Molar mass | 146252.08 g·mol−1 |
  (what is this?) (verify) | |
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.[1] It targets interferon a.[2]
Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.[3][4][5]
References
- ↑ "Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus". Immunotherapy 9 (1): 57–70. January 2017. doi:10.2217/imt-2016-0090. PMID 28000522.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf.
- ↑ "Press release: New Hope for Lupus Patients" (in en). MedImmune. 11 August 2015. https://www.medimmune.com/about-us/media/new-hope-for-lupus-patients-20150811.html.
- ↑ "Sifalimumab" (in en). AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800024071.
- ↑ "Sifalimumab". NHS Specialist Pharmacy Service. https://www.sps.nhs.uk/medicines/sifalimumab/.
 |  |
